News

A 2011 study entitled, “Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study” identified the fact that prevalence of heart failure with preserved ejection fraction is increasing in the patient population, and that patient prognosis worsens among those…

Exercise and fitness are two health factors that invariably affect prognoses for most chronic, progressive diseases. Given the stress and immobility that come as a result of illness, maintaining fitness to the best of the patient’s ability is generally a best practice for maximizing quality of life and lifespan.

November has been designated Pulmonary Hypertension Awareness Month by the Pulmonary Hypertension Association, and the organization is already planning on initiatives throughout the month and beyond to help support research, fundraising, advocacy, and awareness about pulmonary hypertension (PH). PH Awareness Month, which will be hosted by the association, will include activities…

ProMetic Life Sciences Inc. is currently preparing an Orphan Drug Designation (ODD) request for the company’s novel Idiopathic Pulmonary Fibrosis (IPF) drug PBI-4050 to the Food and Drug Administration (FDA). According to the company, an external panel of IPF world experts strongly recommend that PBI-4050 be granted…

The Pulmonary Hypertension Association, a non-profit organization with over 13,000 members and supporters, is joining other organizations from across the globe to commemorate a unified advocacy for pulmonary hypertension (PH) for the month of November. Dubbed Pulmonary Hypertension Awareness Month, November will be packed with activities and…

While it is commonly accepted that patients with scleroderma are at a higher risk for contracting pulmonary hypertension, the field has progressed immensely since the first hypothesis was tested in the laboratory. “Recent Advances in Scleroderma-associated Pulmonary Hypertension,” published in…

October is Liver Awareness Month, and the Pulmonary Hypertension Association together with the American Liver Foundation are sharing with the general public information on a long-established relationship between hepatic disease and pulmonary hypertension. The new initiative aims to spread awareness, enhance patient education and knowledge,…

A recent study conducted in Brazil suggests noninvasive positive pressure ventilation (CPAP) does not contribute to ventilation-related complications in pulmonary hypertension patients. These results are encouraging, as there had been previous reports demonstrating that mechanical ventilation of patients with pulmonary hypertension results in unfavorable hemodynamic effects. Until this study,”…

A new study entitled “Quality of life as a prognostic marker in pulmonary arterial hypertension” published now in Health and Quality of Life Outcomes reports that patients’ health-related quality of life associates closely with PAH patient prognosis, and can identify high-risk PAH patients. Pulmonary arterial hypertension (PAH)…

The Pulmonary Fibrosis Foundation (PFF) applauded the recent news that both Esbriet® (pirfenidone) and Ofev® (nintedanib) were approved by the Food and Drug Administration (FDA) to treat idiopathic pulmonary fibrosis (IPF). These drugs are the first FDA-approved disease-specific therapies for IPF in the US.

The results from the randomized controlled AMBITION study to determine the efficacy of treating patients with Pulmonary Arterial Hypertension (PAH) with a combination of ambrisentan/tadalafil, when compared to ambrisenan or taladafil as monotherapies, were presented at this year’s European Respiratory Society (ERS) International Congress. Combination therapies are a form…

A new study on pulmonary arterial hypertension (PAH) entitled “Echocardiographic Assessment of Estimated Right Atrial Pressure and Size Predicts Mortality in Pulmonary Arterial Hypertension” was published in Chest by Dr. Christopher Austin, part of Dr. Brian Shapiro’s group from Division of Cardiovascular Disease at the…